STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
暂无分享,去创建一个
M. Karin | J. Fuster | J. García-Valdecasas | M. Monte | J. Marin | J. Fernandez-Checa | F. Civeira | C. Garcia-Ruiz | L. Baila-Rueda | A. Cenarro | S. Núñez | J. Ferrer | L. Conde de la Rosa | V. Ribas | A. Baulies | C. Vallejo | J. García‐Valdecasas | J. Fernández-Checa | Laura Conde de la Rosa
[1] G. Ning,et al. High Serum Levels of Cholesterol Increase Anti-tumor Functions of Nature Killer Cells and Reduce Growth of Liver Tumors in Mice. , 2020, Gastroenterology.
[2] J. Fernandez-Checa,et al. STARD1 and NPC1 expression as pathological markers associated with astrogliosis in post-mortem brains from patients with Alzheimer's disease and Down syndrome , 2020, Aging.
[3] J. Marin,et al. Models for Understanding Resistance to Chemotherapy in Liver Cancer , 2019, Cancers.
[4] R. Andrade,et al. Endoplasmic Reticulum Stress-induced Upregulation of STARD1 Promotes Acetaminophen-induced Acute Liver Failure. , 2019, Gastroenterology.
[5] S. Strom,et al. Guide to the Assessment of Mature Liver Gene Expression in Stem Cell-Derived Hepatocytes , 2019, Stem cells and development.
[6] W. Pandak,et al. The acidic pathway of bile acid synthesis: Not just an alternative pathway , 2019, Liver research.
[7] J. Fernandez-Checa,et al. Cholesterol enrichment in liver mitochondria impairs oxidative phosphorylation and disrupts the assembly of respiratory supercomplexes , 2019, Redox biology.
[8] H. Nittono,et al. Mitochondrial oxysterol biosynthetic pathway gives evidence for CYP7B1 as controller of regulatory oxysterols , 2019, The Journal of Steroid Biochemistry and Molecular Biology.
[9] D. Schuppan,et al. Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis , 2019, Hepatology.
[10] D. Calvisi,et al. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans , 2019, Gut.
[11] Lei Zhao,et al. Cholesterol attenuated the progression of DEN-induced hepatocellular carcinoma via inhibiting SCAP mediated fatty acid de novo synthesis. , 2019, Biochemical and biophysical research communications.
[12] Hironori Yamamoto,et al. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high‐fat diet , 2019, Cancer science.
[13] M. Febbraio,et al. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They? , 2019, Cell metabolism.
[14] M. Parr,et al. Conversion of chenodeoxycholic acid to cholic acid by human CYP8B1 , 2018, Biological chemistry.
[15] Jun Yu,et al. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling , 2018, Nature Communications.
[16] M. Karin,et al. ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P , 2018, Cell.
[17] Hongyang Wang,et al. Cholesterol inhibits hepatocellular carcinoma invasion and metastasis by promoting CD44 localization in lipid rafts. , 2018, Cancer letters.
[18] G. Giannelli,et al. Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients , 2018, The International journal of biological markers.
[19] Jun Yu,et al. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target , 2018, Science Translational Medicine.
[20] Rohit Kohli,et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids , 2018, Hepatology.
[21] K. Machida,et al. The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading , 2017, Redox biology.
[22] S. Ferdinandusse,et al. Bile acid analysis in human disorders of bile acid biosynthesis. , 2017, Molecular Aspects of Medicine.
[23] J. Park,et al. Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis in mice , 2017, Hepatology.
[24] A. Franke,et al. Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis , 2017, Nature Medicine.
[25] E. Wagner,et al. Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation , 2017, The Journal of experimental medicine.
[26] R. Green,et al. Endoplasmic Reticulum Stress Regulates Hepatic Bile Acid Metabolism in Mice , 2016, Cellular and molecular gastroenterology and hepatology.
[27] J. Fernandez-Checa,et al. Mitochondria, cholesterol and cancer cell metabolism , 2016, Clinical and Translational Medicine.
[28] J. Bruix,et al. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.
[29] T. Tsai,et al. Body mass index and cholesterol level predict surgical outcome in patients with hepatocellular carcinoma in Taiwan - a cohort study , 2016, Oncotarget.
[30] Hua Li,et al. Bile acids promote diethylnitrosamine-induced hepatocellular carcinoma via increased inflammatory signaling. , 2016, American journal of physiology. Gastrointestinal and liver physiology.
[31] D. Brenner,et al. Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial) , 2015, Hepatology.
[32] M. Karin,et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. , 2014, Cancer cell.
[33] S. Dooley,et al. Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. , 2013, The Journal of clinical investigation.
[34] H. Land,et al. Anticancer activity of the cholesterol exporter ABCA1 gene. , 2012, Cell reports.
[35] A. Sanyal,et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. , 2012, Cell metabolism.
[36] F. Bäckhed,et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. , 2013, Cell metabolism.
[37] B. J. Clark,et al. The mammalian START domain protein family in lipid transport in health and disease. , 2012, The Journal of endocrinology.
[38] P. Siersema,et al. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. , 2010, Biochimica et biophysica acta.
[39] Jun Hee Lee,et al. Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.
[40] Shelly C. Lu,et al. CD133+ liver cancer stem cells from methionine adenosyl transferase 1A–deficient mice demonstrate resistance to transforming growth factor (TGF)‐β–induced apoptosis , 2009, Hepatology.
[41] J. Fernandez-Checa,et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. , 2009, Journal of hepatology.
[42] B. Stiles,et al. Expansion of CD133‐Expressing Liver Cancer Stem Cells in Liver‐Specific Phosphatase and Tensin Homolog Deleted on Chromosome 10‐Deleted Mice , 2009, Stem cells.
[43] M. Saito,et al. Cholesterol effects on BAX pore activation. , 2008, Journal of molecular biology.
[44] J. Prieto,et al. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. , 2008, Cancer research.
[45] J. Martinou,et al. Bax activation and stress-induced apoptosis delayed by the accumulation of cholesterol in mitochondrial membranes , 2008, Cell Death and Differentiation.
[46] Michael F Clarke,et al. The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.
[47] J. Ward,et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. , 2007, Carcinogenesis.
[48] Yun Yen,et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. , 2007, Cancer research.
[49] A. Colell,et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. , 2006, Cell metabolism.
[50] Richard J. Thompson,et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency , 2006, Hepatology.
[51] P. Hylemon,et al. Overexpression of cholesterol transporter StAR increases In Vivo rates of bile acid synthesis in the rat and mouse , 2004, Hepatology.
[52] Michael J Thun,et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.
[53] P. Hylemon,et al. Transport of Cholesterol into Mitochondria Is Rate-limiting for Bile Acid Synthesis via the Alternative Pathway in Primary Rat Hepatocytes* , 2002, The Journal of Biological Chemistry.
[54] Harri Vainio,et al. Overweight, obesity, and cancer risk. , 2002, The Lancet. Oncology.
[55] E. Sandgren,et al. Hepatocyte transplantation into diseased mouse liver. Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytes. , 2000, The American journal of pathology.
[56] ndrea,et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.
[57] P. Elustondo,et al. Mitochondrial cholesterol import. , 2017, Biochimica et biophysica acta. Molecular and cell biology of lipids.
[58] C. Tomasetto,et al. START ships lipids across interorganelle space. , 2014, Biochimie.
[59] J. Llovet,et al. Medical therapies for hepatocellular carcinoma: a critical view of the evidence , 2013, Nature Reviews Gastroenterology &Hepatology.
[60] C. Gonçalves,et al. [Hepatocellular carcinoma]. , 1988, Arquivos de gastroenterologia.